PKR-IN-C16,99.78%

产品编号:Bellancom-13977A| CAS NO:608512-97-6| 分子式:C13H8N4OS| 分子量:268.29

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-13977A
1000.00 杭州 北京(现货)
Bellancom-13977A
1700.00 杭州 北京(现货)
Bellancom-13977A
3500.00 杭州 北京(现货)
Bellancom-13977A
5500.00 杭州 北京(现货)
Bellancom-13977A
9500.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

PKR-IN-C16

产品介绍 PKR-IN-C16 (Compound C16) 是一种特异的双链 RNA 依赖蛋白激酶 (PKR) 抑制剂。PKR-IN-C16 具有良好的神经保护作用,可挽救急性脑损伤。
生物活性

PKR-IN-C16 (Compound C16) is a specific double-stranded RNA-dependent protein kinase (PKR) inhibitor. PKR-IN-C16 shows promising neuroprotective properties and can rescue acute brain lesions.

体外研究

PKR-IN-C16 (Compound C16) is able to unlock the translation blockade induced by PKR in primary neuronal cultures.
PKR-IN-C16 (0.1 or 0.3 μM; 24 h) shows protective effect against the neuronal cell death induced by endoplasmic reticulum stress in SH-SY5Y cells.
PKR-IN-C16 (1-1000 nM; 4 h) prevents not only PKR-phosphorylation but also the activation of caspase-3 induced by Amyloid β in SH-SY5Y cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line: Human SH-SY5Y cells
Concentration: 1, 10, 20, 200, 1000 nM
Incubation Time: 4 h
Result: Markedly reduces the level of phosphorylated PKR in the cells exposed to 20 μM Amyloid β.
体内研究
(In Vivo)

PKR-IN-C16 (Compound C16) (60 or 600 μg/kg; i.p.; 3 times) prevents not only the PKR-induced neuronal loss but also the inflammatory response in the Quinolinic acid (QA) (HY-100807) induced acute excitotoxic rat model

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Normotensive male Wistar rats, excitotoxic neuroinflammatory model, inflammation was induced by unilateral striatal injection of quinolinic acid (QA)
Dosage: 60 or 600 μg/kg
Administration: Intraperitoneal injection; 24 h, 2 h before QA injection and 24 h post-QA injection
Result: Reduced expression of the active catalytic domain of the PKR, prevented increase of IL-1β levels on the contralateral side (97% inhibition) at 600 μg/kg. Decreased by 47% the neuronal loss and by 37% the number of positive cleaved caspase-3 neurons induced by QA injection at 600 μg/kg.
体内研究

PKR-IN-C16 (Compound C16) (60 or 600 μg/kg; i.p.; 3 times) prevents not only the PKR-induced neuronal loss but also the inflammatory response in the Quinolinic acid (QA) (HY-100807) induced acute excitotoxic rat model

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Normotensive male Wistar rats, excitotoxic neuroinflammatory model, inflammation was induced by unilateral striatal injection of quinolinic acid (QA)
Dosage: 60 or 600 μg/kg
Administration: Intraperitoneal injection; 24 h, 2 h before QA injection and 24 h post-QA injection
Result: Reduced expression of the active catalytic domain of the PKR, prevented increase of IL-1β levels on the contralateral side (97% inhibition) at 600 μg/kg. Decreased by 47% the neuronal loss and by 37% the number of positive cleaved caspase-3 neurons induced by QA injection at 600 μg/kg.
体内研究

PKR-IN-C16 (Compound C16) (60 or 600 μg/kg; i.p.; 3 times) prevents not only the PKR-induced neuronal loss but also the inflammatory response in the Quinolinic acid (QA) (HY-100807) induced acute excitotoxic rat model

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Normotensive male Wistar rats, excitotoxic neuroinflammatory model, inflammation was induced by unilateral striatal injection of quinolinic acid (QA)
Dosage: 60 or 600 μg/kg
Administration: Intraperitoneal injection; 24 h, 2 h before QA injection and 24 h post-QA injection
Result: Reduced expression of the active catalytic domain of the PKR, prevented increase of IL-1β levels on the contralateral side (97% inhibition) at 600 μg/kg. Decreased by 47% the neuronal loss and by 37% the number of positive cleaved caspase-3 neurons induced by QA injection at 600 μg/kg.
性状Solid
溶解性数据
In Vitro: 

DMSO : 7.35 mg/mL (27.40 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.7273 mL 18.6365 mL 37.2731 mL
5 mM 0.7455 mL 3.7273 mL 7.4546 mL
10 mM 0.3727 mL 1.8637 mL 3.7273 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服